

Gert J Lammers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9458100/publications.pdf>

Version: 2024-02-01

152
papers

13,247
citations

41344

49
h-index

22832

112
g-index

165
all docs

165
docs citations

165
times ranked

6212
citing authors

#	ARTICLE	IF	CITATIONS
1	A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. <i>Nature Medicine</i> , 2000, 6, 991-997.	30.7	1,945
2	Hypocretin (orexin) deficiency in human narcolepsy. <i>Lancet</i> , The, 2000, 355, 39-40.	13.7	1,666
3	The Role of Cerebrospinal Fluid Hypocretin Measurement in the Diagnosis of Narcolepsy and Other Hypersomnias. <i>Archives of Neurology</i> , 2002, 59, 1553.	4.5	1,052
4	Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. <i>Annals of Neurology</i> , 2001, 50, 381-388.	5.3	451
5	Hypocretin (orexin) loss in Parkinson's disease. <i>Brain</i> , 2007, 130, 1577-1585.	7.6	407
6	CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. <i>Neurology</i> , 2001, 57, 2253-2258.	1.1	400
7	Narcolepsy " clinical spectrum, aetiopathophysiology, diagnosis and treatment. <i>Nature Reviews Neurology</i> , 2019, 15, 519-539.	10.1	364
8	Narcolepsy: Clinical Features, New Pathophysiologic Insights, and Future Perspectives. <i>Journal of Clinical Neurophysiology</i> , 2001, 18, 78-105.	1.7	318
9	Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. <i>Lancet Neurology</i> , The, 2013, 12, 1068-1075.	10.2	301
10	EFNS guidelines on management of narcolepsy. <i>European Journal of Neurology</i> , 2006, 13, 1035-1048.	3.3	235
11	ImmunoChip Study Implicates Antigen Presentation to T Cells in Narcolepsy. <i>PLoS Genetics</i> , 2013, 9, e1003270.	3.5	206
12	The incidence of narcolepsy in Europe: Before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. <i>Vaccine</i> , 2013, 31, 1246-1254.	3.8	205
13	Hypocretin (orexin) loss in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1642-1650.	3.1	195
14	Gammahydroxybutyrate and Narcolepsy: A Double-Blind Placebo-Controlled Study. <i>Sleep</i> , 1993, 16, 216-220.	1.1	184
15	Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy. <i>Sleep Medicine</i> , 2020, 67, 128-136.	1.6	182
16	Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. <i>Nature Genetics</i> , 2010, 42, 786-789.	21.4	170
17	Hypocretin Deficiency in Narcoleptic Humans Is Associated with Abdominal Obesity. <i>Obesity</i> , 2003, 11, 1147-1154.	4.0	169
18	DQB1 Locus Alone Explains Most of the Risk and Protection in Narcolepsy with Cataplexy in Europe. <i>Sleep</i> , 2014, 37, 19-25.	1.1	164

#	ARTICLE	IF	CITATIONS
19	Challenges in Diagnosing Narcolepsy without Cataplexy: A Consensus Statement. <i>Sleep</i> , 2014, 37, 1035-1042.	1.1	145
20	Normal hypocretin-1 levels in Parkinson's disease patients with excessive daytime sleepiness. <i>Neurology</i> , 2002, 58, 498-499.	1.1	133
21	Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. <i>Neurology</i> , 2004, 62, 138-140.	1.1	125
22	The clinical features of cataplexy: A questionnaire study in narcolepsy patients with and without hypocretin-1 deficiency. <i>Sleep Medicine</i> , 2011, 12, 12-18.	1.6	121
23	Spontaneous Food Choice in Narcolepsy. <i>Sleep</i> , 1996, 19, 75-76.	1.1	119
24	Diagnosis of central disorders of hypersomnolence: A reappraisal by European experts. <i>Sleep Medicine Reviews</i> , 2020, 52, 101306.	8.5	119
25	Reduction of Plasma Leptin Levels and Loss of Its Circadian Rhythmicity in Hypocretin (Orexin)-Deficient Narcoleptic Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 805-809.	3.6	110
26	Cataplexy Leading to the Diagnosis of Niemann-Pick Disease Type C. <i>Pediatric Neurology</i> , 2006, 35, 82-84.	2.1	107
27	Convergence of circadian and sleep regulatory mechanisms on hypocretin-1. <i>Neuroscience</i> , 2004, 129, 727-732.	2.3	103
28	CSF hypocretin levels in Guillain-Barré syndrome and other inflammatory neuropathies. <i>Neurology</i> , 2003, 61, 823-825.	1.1	97
29	Possible confusion between primary hypersomnia and adult attention-deficit/hyperactivity disorder. <i>Psychiatry Research</i> , 2006, 143, 293-297.	3.3	94
30	Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	90
31	The Number of Hypothalamic Hypocretin (Orexin) Neurons Is Not Affected in Prader-Willi Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5466-5470.	3.6	87
32	Altered Skin-Temperature Regulation in Narcolepsy Relates to Sleep Propensity. <i>Sleep</i> , 2006, 29, 1444-1449.	1.1	86
33	Novel Approach Identifies SNPs in SLC2A10 and KCNK9 with Evidence for Parent-of-Origin Effect on Body Mass Index. <i>PLoS Genetics</i> , 2014, 10, e1004508.	3.5	80
34	Narcolepsy: Immunological aspects. <i>Sleep Medicine Reviews</i> , 2008, 12, 95-107.	8.5	79
35	Psychotic symptoms in narcolepsy: phenomenology and a comparison with schizophrenia. <i>General Hospital Psychiatry</i> , 2009, 31, 146-154.	2.4	76
36	Weak with laughter. <i>Lancet</i> , The, 1999, 354, 838.	13.7	71

#	ARTICLE	IF	CITATIONS
37	Manipulation of Core Body and Skin Temperature Improves Vigilance and Maintenance of Wakefulness in Narcolepsy. <i>Sleep</i> , 2008, 31, 233-240.	1.1	70
38	European guideline and expert statements on the management of narcolepsy in adults and children. <i>European Journal of Neurology</i> , 2021, 28, 2815-2830.	3.3	67
39	Hypocretin/orexin disturbances in neurological disorders. <i>Sleep Medicine Reviews</i> , 2009, 13, 9-22.	8.5	66
40	Narcolepsy-Associated HLA Class I Alleles Implicate Cell-Mediated Cytotoxicity. <i>Sleep</i> , 2016, 39, 581-587.	1.1	66
41	Sustained attention to response task (SART) shows impaired vigilance in a spectrum of disorders of excessive daytime sleepiness. <i>Journal of Sleep Research</i> , 2012, 21, 390-395.	3.2	61
42	Chronotypes and circadian timing in migraine. <i>Cephalalgia</i> , 2018, 38, 617-625.	3.9	60
43	The hypothalamus in episodic brain disorders. <i>Lancet Neurology</i> , The, 2002, 1, 437-444.	10.2	59
44	Narcolepsy as an adverse event following immunization: Case definition and guidelines for data collection, analysis and presentation. <i>Vaccine</i> , 2013, 31, 994-1007.	3.8	58
45	Voxel-based morphometry in hypocretin-deficient narcolepsy. <i>Sleep</i> , 2003, 26, 44-6.	1.1	58
46	A Missense Mutation in Myelin Oligodendrocyte Glycoprotein as a Cause of Familial Narcolepsy with Cataplexy. <i>American Journal of Human Genetics</i> , 2011, 89, 474-479.	6.2	55
47	Association between Hypocretin-1 and Amyloid- β ;42 Cerebrospinal Fluid Levels in Alzheimer's Disease and Healthy Controls. <i>Current Alzheimer Research</i> , 2012, 9, 1119-1125.	1.4	55
48	Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. <i>Journal of Neurology</i> , 2007, 254, 1607-1608.	3.6	54
49	Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment. <i>Vaccine</i> , 2018, 36, 6202-6211.	3.8	53
50	Pulsatile LH release is diminished, whereas FSH secretion is normal, in hypocretin-deficient narcoleptic men. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 287, E630-E636.	3.5	51
51	Severe fatigue in narcolepsy with cataplexy. <i>Journal of Sleep Research</i> , 2012, 21, 163-169.	3.2	50
52	Reward-Seeking Behavior in Human Narcolepsy. <i>Journal of Clinical Sleep Medicine</i> , 2011, 07, 293-300.	2.6	50
53	Comparing Treatment Effect Measurements in Narcolepsy: The Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness Test. <i>Sleep</i> , 2015, 38, 1051-1058.	1.1	49
54	Focusing on vigilance instead of sleepiness in the assessment of narcolepsy: high sensitivity of the Sustained Attention to Response Task (SART). <i>Sleep</i> , 2006, 29, 187-91.	1.1	49

#	ARTICLE	IF	CITATIONS
55	Effects of startle and laughter in cataplectic subjects: a neurophysiological study between attacks. <i>Clinical Neurophysiology</i> , 2000, 111, 1276-1281.	1.5	47
56	The European Narcolepsy Network (<scp>EU</scp>â€‹<scp>NN</scp>) database. <i>Journal of Sleep Research</i> , 2016, 25, 356-364.	3.2	47
57	Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy. <i>Journal of Neuroimmunology</i> , 2006, 174, 187-191.	2.3	46
58	Neurology and psychiatry: waking up to opportunities of sleep. : State of the art and clinical/research priorities for the next decade. <i>European Journal of Neurology</i> , 2015, 22, 1337-1354.	3.3	46
59	Cataplexy: â€˜tonic immobilityâ€™ rather than â€˜REM-sleep atoniaâ€™?. <i>Sleep Medicine</i> , 2002, 3, 471-477.	1.6	45
60	Somatotropic axis in hypocretin-deficient narcoleptic humans: altered circadian distribution of GH-secretory events. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2003, 284, E641-E647.	3.5	45
61	Manipulation of skin temperature improves nocturnal sleep in narcolepsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 1354-1357.	1.9	45
62	Circadian distribution of motor activity and immobility in narcolepsy: Assessment with continuous motor activity monitoring. <i>Psychophysiology</i> , 1995, 32, 286-291.	2.4	44
63	Repetitive CMAPs: Mechanisms of neural and synaptic genesis. , 1996, 19, 1127-1133.		44
64	Dynamics of the Pituitary-Adrenal Ensemble in Hypocretin-Deficient Narcoleptic Humans: Blunted Basal Adrenocorticotropin Release and Evidence for Normal Time-Keeping by the Master Pacemaker. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 5085-5091.	3.6	44
65	European guideline and expert statements on the management of narcolepsy in adults and children. <i>Journal of Sleep Research</i> , 2021, 30, e13387.	3.2	44
66	Delusional Confusion of Dreaming and Reality in Narcolepsy. <i>Sleep</i> , 2014, 37, 419-422.	1.1	41
67	Hypocretin (orexin) loss and sleep disturbances in Parkinson's Disease. <i>Brain</i> , 2007, 131, e88-e88.	7.6	39
68	Corticospinal excitability during laughter: implications for cataplexy and the comparison with REM sleep atonia. <i>Journal of Sleep Research</i> , 2004, 13, 257-264.	3.2	38
69	Coexisting narcolepsy (with and without cataplexy) and multiple sclerosis. <i>Journal of Neurology</i> , 2018, 265, 2071-2078.	3.6	36
70	Exploring the clinical features of narcolepsy type 1 versus narcolepsy type 2 from European Narcolepsy Network database with machine learning. <i>Scientific Reports</i> , 2018, 8, 10628.	3.3	36
71	Ritanserin, A 5-HT2 Receptor Blocker, as Add-on Treatment in Narcolepsy. <i>Sleep</i> , 1991, 14, 109-115.	1.1	34
72	Altered setting of the pituitary-thyroid ensemble in hypocretin-deficient narcoleptic men. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 288, E892-E899.	3.5	34

#	ARTICLE	IF	CITATIONS
73	Glucose and Fat Metabolism in Narcolepsy and the Effect of Sodium Oxybate: A Hyperinsulinemic-Euglycemic Clamp Study. <i>Sleep</i> , 2014, 37, 795-801.	1.1	34
74	Aberrant Food Choices after Satiating in Human Orexin-Deficient Narcolepsy Type 1. <i>Sleep</i> , 2016, 39, 1951-1959.	1.1	34
75	Alterations in diurnal rhythmicity in patients treated for nonfunctioning pituitary macroadenoma: a controlled study and literature review. <i>European Journal of Endocrinology</i> , 2014, 171, 217-228.	3.7	33
76	Vigilance: discussion of related concepts and proposal for a definition. <i>Sleep Medicine</i> , 2021, 83, 175-181.	1.6	33
77	Hypocretin/orexin and sleep: implications for the pathophysiology and diagnosis of narcolepsy. <i>Current Opinion in Neurology</i> , 2002, 15, 739-745.	3.6	31
78	CSF hypocretin-1 levels are normal in multiple-system atrophy. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 342-344.	2.2	30
79	Sodium oxybate is an effective and safe treatment for narcolepsy. <i>Sleep Medicine</i> , 2010, 11, 105-106.	1.6	29
80	Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy. <i>Neuroscience Letters</i> , 2003, 341, 13-16.	2.1	27
81	A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy. <i>Journal of Sleep Research</i> , 2012, 21, 479-480.	3.2	27
82	Time- and state-dependent analysis of autonomic control in narcolepsy: higher heart rate with normal heart rate variability independent of sleep fragmentation. <i>Journal of Sleep Research</i> , 2015, 24, 206-214.	3.2	27
83	Is motor inhibition during laughter due to emotional or respiratory influences?. <i>Psychophysiology</i> , 2004, 41, 254-258.	2.4	26
84	Hypocretin/orexin and sleep: implications for the pathophysiology and diagnosis of narcolepsy. <i>Current Opinion in Neurology</i> , 2002, 15, 739-745.	3.6	25
85	Restless legs syndrome in migraine patients: prevalence and severity. <i>European Journal of Neurology</i> , 2016, 23, 1110-1116.	3.3	25
86	Effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 300, E1069-E1075.	3.5	24
87	Increased heart rate variability but normal resting metabolic rate in hypocretin/orexin-deficient human narcolepsy. <i>Journal of Clinical Sleep Medicine</i> , 2008, 4, 248-54.	2.6	22
88	Improved vigilance after sodium oxybate treatment in narcolepsy: a comparison between in-field and in-laboratory measurements. <i>Journal of Sleep Research</i> , 2016, 25, 486-496.	3.2	20
89	Voxel-Based Morphometry in Hypocretin-Deficient Narcolepsy. <i>Sleep</i> , 2003, , .	1.1	19
90	The MSLT: More Objections than Benefits as a Diagnostic Gold Standard?. <i>Sleep</i> , 2014, 37, 1027-1028.	1.1	19

#	ARTICLE	IF	CITATIONS
91	Clomipramine withdrawal in newborns. Archives of Disease in Childhood: Fetal and Neonatal Edition, 1999, 81, F77-F77.	2.8	19
92	Immunohistochemical screening for antibodies in recent onset type 1 narcolepsy and after H1N1 vaccination. Journal of Neuroimmunology, 2015, 283, 58-62.	2.3	18
93	HLA dosage effect in narcolepsy with cataplexy. Immunogenetics, 2015, 67, 1-6.	2.4	18
94	Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1. Journal of Sleep Research, 2019, 28, e12684.	3.2	18
95	Plasma Total Ghrelin and Leptin Levels in Human Narcolepsy and Matched Healthy Controls: Basal Concentrations and Response to Sodium Oxybate. Journal of Clinical Sleep Medicine, 2013, 09, 797-803.	2.6	18
96	Idling for Decades: A European Study on Risk Factors Associated with the Delay Before a Narcolepsy Diagnosis. Nature and Science of Sleep, 0, Volume 14, 1031-1047.	2.7	18
97	The multiple sleep latency test: a paradoxical test?. Clinical Neurology and Neurosurgery, 1992, 94, 108-110.	1.4	16
98	H1N1 hemagglutinin-specific HLA-DQ6-restricted CD4+ T cells can be readily detected in narcolepsy type 1 patients and healthy controls. Journal of Neuroimmunology, 2019, 332, 167-175.	2.3	15
99	Daytime sleep state misperception in a tertiary sleep centre population. Sleep Medicine, 2020, 69, 78-84.	1.6	15
100	A patient with narcolepsy with cataplexy and multiple sclerosis: two different diseases that may share pathophysiologic mechanisms?. Sleep Medicine, 2013, 14, 695-696.	1.6	14
101	Eating Decisions Based on Alertness Levels After a Single Night of Sleep Manipulation: A Randomized Clinical Trial. Sleep, 2017, 40, .	1.1	14
102	Understanding the association between sleep, shift work and COVID-19 vaccine immune response efficacy: Protocol of the Sâ€CORE study. Journal of Sleep Research, 2022, 31, e13496.	3.2	14
103	Reduced Numbers of Corticotropinâ€Releasing Hormone Neurons in Narcolepsy Type 1. Annals of Neurology, 2022, 91, 282-288.	5.3	14
104	Pandemic influenza vaccine & narcolepsy: simulations on the potential impact of bias. Expert Review of Vaccines, 2016, 15, 573-584.	4.4	13
105	Widespread white matter connectivity abnormalities in narcolepsy type 1: A diffusion tensor imaging study. NeuroImage: Clinical, 2019, 24, 101963.	2.7	13
106	Core Body and Skin Temperature in Type 1 Narcolepsy in Daily Life; Effects of Sodium Oxybate and Prediction of Sleep Attacks. Sleep, 2016, 39, 1941-1949.	1.1	12
107	Enhanced food-related responses in the ventral medial prefrontal cortex in narcolepsy type 1. Scientific Reports, 2018, 8, 16391.	3.3	12
108	A Mobile App for Longterm Monitoring of Narcolepsy Symptoms: Design, Development, and Evaluation. JMIR MHealth and UHealth, 2020, 8, e14939.	3.7	12

#	ARTICLE	IF	CITATIONS
109	Ritanserin, a 5-HT ₂ receptor blocker, as add-on treatment in narcolepsy. <i>Sleep</i> , 1991, 14, 130-2.	1.1	12
110	Drugs Used in Narcolepsy and Other Hypersomnias. <i>Sleep Medicine Clinics</i> , 2018, 13, 183-189.	2.6	11
111	New 2013 incidence peak in childhood narcolepsy: more than vaccination?. <i>Sleep</i> , 2021, 44, .	1.1	11
112	CSF hypocretin-1 levels are normal in patients with amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 487-489.	2.1	10
113	Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial. <i>CNS Drugs</i> , 2020, 34, 773-784.	5.9	10
114	Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1. <i>Sleep</i> , 2022, 45, .	1.1	10
115	Altered Circadian Rhythm of Melatonin Concentrations in Hypocretin-Deficient Men. <i>Chronobiology International</i> , 2012, 29, 356-362.	2.0	9
116	The effects of sodium oxybate on core body and skin temperature regulation in narcolepsy. <i>Journal of Sleep Research</i> , 2015, 24, 566-575.	3.2	9
117	Orexin-A measurement in narcolepsy: A stability study and a comparison of LC-MS/MS and immunoassays. <i>Clinical Biochemistry</i> , 2021, 90, 34-39.	1.9	9
118	The influences of task repetition, napping, time of day, and instruction on the Sustained Attention to Response Task. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2014, 36, 1055-1065.	1.3	8
119	Effect of treatment on cognitive and attention problems in children with narcolepsy type 1. <i>Sleep</i> , 2020, 43, .	1.1	8
120	Effects of solriamfetol on onâ€theâ€road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea. <i>Human Psychopharmacology</i> , 2022, 37, .	1.5	8
121	Isolated Cataplexy of more than 40 Years' Duration. <i>British Journal of Psychiatry</i> , 1991, 159, 719-721.	2.8	7
122	Month of birth is not a risk factor for narcolepsy with cataplexy in the Netherlands. <i>Journal of Sleep Research</i> , 2011, 20, 522-525.	3.2	7
123	Sleep-Mediated Heart Rate Variability after Bilateral Carotid Body Tumor Resection. <i>Sleep</i> , 2015, 38, 633-639.	1.1	7
124	Comparing objective wakefulness and vigilance tests to onâ€theâ€road driving performance in narcolepsy and idiopathic hypersomnia. <i>Journal of Sleep Research</i> , 2022, 31, e13518.	3.2	7
125	Carotid body tumors are not associated with an increased risk for sleep-disordered breathing. <i>Sleep and Breathing</i> , 2014, 18, 103-109.	1.7	6
126	Update on the Treatment of Idiopathic Hypersomnia. <i>Current Sleep Medicine Reports</i> , 2019, 5, 207-214.	1.4	6

#	ARTICLE	IF	CITATIONS
127	The Sustained Attention to Response Task Shows Lower Cingulo-Opercular and Frontoparietal Activity in People with Narcolepsy Type 1: An fMRI Study on the Neural Regulation of Attention. <i>Brain Sciences</i> , 2020, 10, 419.	2.3	6
128	The orexin/hypocretin system in neuropsychiatric disorders: Relation to signs and symptoms. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 180, 343-358.	1.8	6
129	High frequency repetitive transcranial magnetic stimulation over the motor cortex: No diagnostic value for narcolepsy/cataplexy. <i>Journal of Neurology</i> , 2007, 254, 1459-1461.	3.6	5
130	Short-Term Effects of Electroconvulsive Therapy on Subjective and Actigraphy-Assessed Sleep Parameters in Severely Depressed Inpatients. <i>Depression Research and Treatment</i> , 2015, 2015, 1-7.	1.3	5
131	Usefulness of the maintenance of wakefulness test in central disorders of hypersomnolence: a scoping review. <i>Sleep</i> , 2022, 45, .	1.1	5
132	Letter to the Editor. <i>Sleep Medicine</i> , 2002, 3, 531-532.	1.6	4
133	Conventional autoantibodies against brain antigens are not routinely detectable in serum and CSF of narcolepsy type 1 and 2 patients. <i>Sleep Medicine</i> , 2020, 75, 188-191.	1.6	4
134	Reply to Micoulaud-Franchi etÂal. Commentary on diagnosis of central disorders of hypersomnolence: From clinic to clinic via ontology and semantic analysis on a bullet point path. <i>Sleep Medicine Reviews</i> , 2020, 52, 101329.	8.5	4
135	Reply to Maski K etÂal. commentary on diagnosis of central disorders of hypersomnolence: Challenges in defining central disorders of hypersomnolence. <i>Sleep Medicine Reviews</i> , 2020, 52, 101326.	8.5	4
136	Pharmacological management of narcolepsy. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1739-1746.	1.8	3
137	Intranasal hypocretin-1: Making sense of scents?. <i>Sleep Medicine</i> , 2011, 12, 939-940.	1.6	3
138	The Role of the Suprachiasmatic Nucleus in Cardiac Autonomic Control during Sleep. <i>PLoS ONE</i> , 2016, 11, e0152390.	2.5	3
139	The tuberomamillary nucleus in neuropsychiatric disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 180, 389-400.	1.8	3
140	Sleep Scoring at a Lower Resolution. <i>Sleep</i> , 1997, 20, 641-644.	1.1	2
141	The development of hypocretin deficiency in narcolepsy type 1 can be swift and closely linked to symptom onset: clues from a singular case. <i>Sleep</i> , 2019, 42, .	1.1	2
142	On-the-road driving performance of patients with central disorders of hypersomnolence. <i>Traffic Injury Prevention</i> , 2021, 22, 120-126.	1.4	2
143	Repetitive CMAPs: Mechanisms of neural and synaptic genesis. <i>Muscle and Nerve</i> , 1996, 19, 1127-1133.	2.2	2
144	Hypocretin-1 measurements in cerebrospinal fluid using radioimmunoassay: within and between assay reliability and limit of quantification. <i>Sleep</i> , 2022, , .	1.1	2

#	ARTICLE	IF	CITATIONS
145	Disorders of Sleep and Circadian Rhythms. , 2007, , 409-426.		1
146	HLA associations in narcolepsy type 1 persist after the 2009 H1N1 pandemic. Journal of Neuroimmunology, 2020, 342, 577210.	2.3	1
147	“Sleepiness” in obstructive sleep apnea: getting into deep water. Sleep Medicine, 2022, 92, 64-66.	1.6	1
148	Are Headache and Narcolepsy Associated?. Cephalalgia, 2003, 23, 775-775.	3.9	0
149	Bringing posttraumatic sleep“wake disorders out of the dark. Neurology, 2016, 86, 1934-1935.	1.1	0
150	Sleep in 2016: methodological issues and progress. Lancet Neurology, The, 2017, 16, 15-17.	10.2	0
151	Hypocretin/Orexin and Sleep. , 2005, , 279-290.		0
152	Narcolepsy with cataplexy. , 2017, , .		0